Literature DB >> 3533644

Role of iron in adriamycin biochemistry.

C Myers, L Gianni, J Zweier, J Muindi, B K Sinha, H Eliot.   

Abstract

Adriamycin forms a chelate with Fe(III) that exhibits complex redox chemistry. The drug ligand is able to directly reduce the bound Fe(III) with the concomitant production of a one-electron oxidized drug radical. This Fe(II) can reduce oxygen to hydrogen peroxide and cleave the peroxide to yield the hydroxyl radical. In addition, the drug X Fe complex can catalyze the transfer of electrons from reduced glutathione to molecular oxygen to yield superoxide, hydrogen peroxide, and hydroxyl radicals. The adriamycin X Fe complex binds to DNA to form a ternary drug X Fe X DNA complex, which is also able to catalyze the thiol-dependent reduction of oxygen and the formation of hydroxyl radical from hydrogen peroxide. As a consequence of this chemistry, the adriamycin X Fe complex can cleave DNA on the addition of glutathione or hydrogen peroxide. Although less well defined, the adriamycin X Fe complex can bind to cell membranes and cause oxidative destruction of these membranes in the presence of thiols or hydrogen peroxide.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533644

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  14 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

Review 2.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

3.  Immobilization of a primary amine-containing drug, adriamycin. Coupling to crosslinked polyvinyl alcohol and mechanistic comparison of hydrolytic stability.

Authors:  L B Wingard; K Narasimhan
Journal:  Appl Biochem Biotechnol       Date:  1988-11       Impact factor: 2.926

4.  Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium.

Authors:  Shasi V Kalivendi; Eugene A Konorev; Sonya Cunningham; Sravan K Vanamala; Eugene H Kaji; Joy Joseph; B Kalyanaraman
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

5.  Formation of adriamycin--DNA adducts in vitro.

Authors:  C Cullinane; S M Cutts; A van Rosmalen; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

Review 6.  Roles of iron in neoplasia. Promotion, prevention, and therapy.

Authors:  E D Weinberg
Journal:  Biol Trace Elem Res       Date:  1992-08       Impact factor: 3.738

Review 7.  Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 8.  A review of the use of chemoprotectants in cancer chemotherapy.

Authors:  C Lewis
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

9.  Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.

Authors:  E H Herman; J Zhang; V J Ferrans
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Characterization of covalent adriamycin-DNA adducts.

Authors:  S M Zeman; D R Phillips; D M Crothers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.